ABI has entered into a contract research agreement with Austin-based startup, Macromoltek, to test the viability of new computational antibody design algorithms experimentally. Macromoltek has an automated antibody design platform for difficult infectious diseases and cancer targets.  The computational platform will enable designing a novel antibody to bind to a given target protein. ABI has partnered with Macromoltek to perform experimental work. ABI Coordinator, Nancy Lyon is leading a team of ACC interns to express and test binding of computationally predicted antibodies. This work could aid in reducing the time in new drug discovery which would revolutionize the development of therapeutics for serious diseases such as cancers, MS, rheumatoid arthritis and Crohn’s Disease.